#BEGIN_DRUGCARD DB08900

# AHFS_Codes:
56:92

# ATC_Codes:
A16AX08

# Absorption:
The pharmacokinetic profile of teduglutide (when administered subcutaneously) is described by a one-compartment model with first order absorption in the abdomen, arm, and thigh. With escalating doses, teduglutide demonstrates linear pharmacokinetics. 
Absolute bioavailability, SubQ = 88%;
Tmax, SubQ = 3-5 hours;  
Cmax, 0.05 mg/kg SubQ, SBS patients = 36 ng/mL; 
AUC, 0.05 mg/kg SubQ, SBS patients = 0.15 µg•hr/mL;
Teduglutide does not accumulate following multiple subcutaneous administrations.

# Biotransformation:
Although a formal investigation has not been conducted, it is expected because teduglutide is a peptide-based drug, it will be degraded into smaller peptides and amino acids via catabolic pathways. The cytochrome P450 enzyme system is not involved in the metabolism of this drug.

# Brand_Mixtures:
Not Available

# Brand_Names:
Gattex
Revestive

# CAS_Registry_Number:
197922-42-2

# ChEBI_ID:
72305

# Chemical_Formula:
C164H252N44O55S

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
>Protein sequence for teduglutide
HGDGSFSDEMNTILDNLAARDFINWLIQTKITD

# Creation_Date:
2013-06-05 23:11:44 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.

# Dosage_Forms:
Injection, powder, for solution	Subcutaneous

# Drug_Category:
Gastrointestinal Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
22570676	Jeppesen PB: Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Therap Adv Gastroenterol. 2012 May;5(3):159-71. doi: 10.1177/1756283X11436318.
23591284	Semrad CE: The Long Road to a New Short-Bowel Therapy: Teduglutide for Clinical Use. Clin Gastroenterol Hepatol. 2013 Apr 13. pii: S1542-3565(13)00471-0. doi: 10.1016/j.cgh.2013.03.030.
23729002	Burness CB, McCormack PL: Teduglutide: A Review of its Use in the Treatment of Patients with Short Bowel Syndrome. Drugs. 2013 Jun 1.

# Drug_Type:
Approved
Biotech

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Teduglutide

# HET_ID:
Not Available

# Half_Life:
Terminal half-life, healthy subjects = 2 hours;
Terminal half-life, SBS patients = 1.3 hours

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support.

# KEGG_Compound_ID:
C16049

# KEGG_Drug_ID:
D06053

# LIMS_Drug_ID:
8916

# Mechanism_Of_Action:
Teduglutide is an analog of naturally occurring human glucagon-like peptide-2 (GLP-2), a peptide secreted by L-cells of the distal intestine in response to meals. GLP-2 increases intestinal and portal blood flow and inhibit gastric acid secretion. Teduglutide binds to the glucagon-like peptide-2 receptors located in enteroendocrine cells, subepithelial myofibroblasts and enteric neurons of the submucosal and myenteric plexus. This causes the release of insulin-like growth factor (IGF)-1, nitric oxide and keratinocyte growth factor (KGF). These growth factors may contribute to the increase in crypt cell growth and surface area of the gastric mucosa. Ultimately, absorption through the intestine is enhanced.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
3752 Da

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
An enhancement of gastrointestinal fluid absorption (750-1000 mL/day) was observed following daily administrations of teduglutide. An increase in villus height and crypt depth of the intestinal mucosa was also noted. A decrease in fecal weight has also been observed. Teduglutide does not prolong the QTc interval.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB08900

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/gattex-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
liquid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
ALX-0600
Teduglutide Recombinant
Teduglutide [rDNA origin]

# Synthesis_Reference:
Not Available

# Toxicity:
The most common adverse reactions (≥ 10%) across all studies with GATTEX are abdominal pain, injection site reactions, nausea, headaches, abdominal distension, upper respiratory tract infection. In addition, vomiting and fluid overload were reported in the SBS studies (1 and 3) at rates ≥ 10%.

# Update_Date:
2013-06-06 00:48:08 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Teduglutide

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
23729002	Burness CB, McCormack PL: Teduglutide: A Review of its Use in the Treatment of Patients with Short Bowel Syndrome. Drugs. 2013 Jun 1.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
GLP2R

# Drug_Target_1_GenBank_ID_Gene:
AF105367

# Drug_Target_1_GenBank_ID_Protein:
4324491

# Drug_Target_1_GeneCard_ID:
GLP2R

# Drug_Target_1_Gene_Name:
GLP2R

# Drug_Target_1_Gene_Sequence:
>1662 bp
ATGAAGCTGGGATCGAGCAGGGCAGGGCCTGGGAGAGGAAGCGCGGGACTCCTGCCTGGC
GTCCACGAGCTGCCCATGGGCATCCCTGCCCCCTGGGGGACCAGTCCTCTCTCCTTCCAC
AGGAAGTGCTCTCTCTGGGCCCCTGGGAGGCCCTTCCTCACTCTGGTCCTGCTGGTTTCC
ATCAAGCAAGTTACAGGATCCCTCCTTGAGGAAACGACTCGGAAGTGGGCTCAGTACAAA
CAGGCATGTCTGAGAGACTTACTCAAGGAACCTTCTGGCATATTTTGTAACGGGACATTT
GATCAGTACGTGTGTTGGCCTCATTCTTCTCCTGGAAATGTCTCTGTACCCTGCCCTTCA
TACTTACCTTGGTGGAGTGAAGAGAGCTCAGGAAGGGCCTACAGACACTGCTTGGCTCAG
GGGACTTGGCAGACGATAGAGAACGCCACGGATATTTGGCAGGATGACTCCGAATGCTCC
GAGAACCACAGCTTCAAGCAAAACGTGGACCGTTATGCCTTGCTGTCAACCTTGCAGCTG
ATGTACACCGTGGGATACTCCTTCTCTCTTATCTCCCTCTTCCTGGCTCTCACCCTCCTC
TTGTTTCTTCGAAAACTCCACTGCACGCGCAACTACATCCACATGAACTTGTTTGCTTCT
TTCATCCTGAGAACCCTGGCTGTACTGGTGAAGGACGTCGTCTTCTACAACTCTTACTCC
AAGAGGCCTGACAATGAGAATGGGTGGATGTCCTACCTGTCAGAGATGTCCACCTCCTGC
CGCTCAGTCCAGGTTCTCTTGCATTACTTTGTGGGTGCCAATTACTTATGGCTGCTGGTT
GAAGGCCTCTACCTCCACACGCTGCTGGAGCCCACAGTGCTTCCTGAGAGGCGGCTGTGG
CCCAGATACCTGCTGTTGGGTTGGGCCTTCCCTGTGCTATTTGTTGTACCCTGGGGTTTC
GCCCGTGCACACCTGGAGAACACAGGGTGCTGGACAACAAATGGGAATAAGAAAATCTGG
TGGATCATCCGAGGACCCATGATGCTCTGTGTAACAGTCAATTTCTTCATCTTCCTGAAA
ATTCTCAAGCTTCTCATTTCTAAGCTCAAAGCTCATCAAATGTGCTTCAGAGATTATAAA
TACAGATTGGCAAAATCAACACTGGTCCTCATTCCTTTATTGGGCGTTCATGAGATCCTC
TTCTCTTTCATCACTGATGATCAAGTTGAAGGATTTGCAAAACTTATACGACTTTTCATT
CAGTTGACACTGAGCTCCTTTCATGGGTTCCTGGTGGCCTTGCAGTATGGTTTTGCCAAT
GGAGAAGTGAAGGCTGAGCTGCGGAAATACTGGGTCCGCTTCTTGCTAGCCCGCCACTCA
GGCTGCAGAGCCTGTGTCCTGGGGAAGGACTTCCGGTTCCTAGGAAAATGTCCCAAGAAG
CTCTCGGAAGGAGATGGCGCTGAGAAGCTTCGGAAGCTGCAGCCCTCACTTAACAGTGGG
CGGCTCCTACATCTAGCCATGCGAGGTCTTGGGGAGCTGGGCGCCCAGCCCCAACAGGAC
CATGCACGCTGGCCCCGGGGCAGCAGCCTGTCCGAGTGCAGTGAGGGGGATGTCACCATG
GCCAACACCATGGAGGAGATTCTGGAAGAGAGTGAGATCTAG

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
9990065	Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A: Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1569-73.

# Drug_Target_1_HGNC_ID:
HGNC:4325

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3857

# Drug_Target_1_Locus:
17p13.3

# Drug_Target_1_Molecular_Weight:
63002

# Drug_Target_1_Name:
Glucagon-like peptide 2 receptor

# Drug_Target_1_Number_of_Residues:
553

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00002	7tm_2
PF02793	HRM

# Drug_Target_1_Protein_Sequence:
>Glucagon-like peptide 2 receptor
MKLGSSRAGPGRGSAGLLPGVHELPMGIPAPWGTSPLSFHRKCSLWAPGRPFLTLVLLVS
IKQVTGSLLEETTRKWAQYKQACLRDLLKEPSGIFCNGTFDQYVCWPHSSPGNVSVPCPS
YLPWWSEESSGRAYRHCLAQGTWQTIENATDIWQDDSECSENHSFKQNVDRYALLSTLQL
MYTVGYSFSLISLFLALTLLLFLRKLHCTRNYIHMNLFASFILRTLAVLVKDVVFYNSYS
KRPDNENGWMSYLSEMSTSCRSVQVLLHYFVGANYLWLLVEGLYLHTLLEPTVLPERRLW
PRYLLLGWAFPVLFVVPWGFARAHLENTGCWTTNGNKKIWWIIRGPMMLCVTVNFFIFLK
ILKLLISKLKAHQMCFRDYKYRLAKSTLVLIPLLGVHEILFSFITDDQVEGFAKLIRLFI
QLTLSSFHGFLVALQYGFANGEVKAELRKYWVRFLLARHSGCRACVLGKDFRFLGKCPKK
LSEGDGAEKLRKLQPSLNSGRLLHLAMRGLGELGAQPQQDHARWPRGSSLSECSEGDVTM
ANTMEEILEESEI

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
This is a receptor for glucagon-like peptide 2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase

# Drug_Target_1_SwissProt_ID:
O95838

# Drug_Target_1_SwissProt_Name:
GLP2R_HUMAN

# Drug_Target_1_Synonyms:
GLP-2 receptor
GLP-2-R
GLP-2R
Glucagon-like peptide 2 receptor precursor

# Drug_Target_1_Theoretical_pI:
9.03

# Drug_Target_1_Transmembrane_Regions:
180-202
211-230
262-286
299-322
338-363
386-406
422-442

#END_DRUGCARD DB08900
